Shares of STAAR Surgical (NASDAQ:STAA – Get Free Report) have been assigned an average rating of “Hold” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $42.83.
STAA has been the topic of several research analyst reports. Canaccord Genuity Group decreased their price target on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a report on Monday, December 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Tuesday, January 7th. Finally, Stephens raised STAAR Surgical to a “hold” rating in a research note on Monday, December 2nd.
Check Out Our Latest Stock Analysis on STAA
Insider Activity at STAAR Surgical
Institutional Investors Weigh In On STAAR Surgical
Several hedge funds have recently added to or reduced their stakes in STAA. JPMorgan Chase & Co. boosted its stake in STAAR Surgical by 411.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after purchasing an additional 172,779 shares during the last quarter. American Capital Management Inc. boosted its holdings in STAAR Surgical by 42.9% in the third quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier’s stock worth $19,051,000 after purchasing an additional 154,037 shares during the last quarter. KBC Group NV increased its position in STAAR Surgical by 5,700.9% during the fourth quarter. KBC Group NV now owns 96,585 shares of the medical instruments supplier’s stock valued at $2,346,000 after acquiring an additional 94,920 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in STAAR Surgical by 25.9% in the second quarter. Dimensional Fund Advisors LP now owns 459,655 shares of the medical instruments supplier’s stock worth $21,884,000 after purchasing an additional 94,422 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in STAAR Surgical by 84.2% during the second quarter. Millennium Management LLC now owns 178,772 shares of the medical instruments supplier’s stock valued at $8,511,000 after buying an additional 81,738 shares during the last quarter. 96.70% of the stock is owned by institutional investors.
STAAR Surgical Trading Down 0.9 %
STAA opened at $23.97 on Friday. The company has a 50 day moving average of $24.73 and a 200 day moving average of $30.62. STAAR Surgical has a 12 month low of $21.13 and a 12 month high of $52.68. The company has a market cap of $1.18 billion, a PE ratio of 54.48 and a beta of 0.63.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Featured Stories
- Five stocks we like better than STAAR Surgical
- 3 Best Fintech Stocks for a Portfolio Boost
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- How to Start Investing in Real Estate
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Which Wall Street Analysts are the Most Accurate?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.